270 related articles for article (PubMed ID: 31646375)
21. Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy.
Sofocleous CT; Garcia AR; Pandit-Taskar N; Do KG; Brody LA; Petre EN; Capanu M; Longing AP; Chou JF; Carrasquillo JA; Kemeny NE
Clin Colorectal Cancer; 2014 Mar; 13(1):27-36. PubMed ID: 24370352
[TBL] [Abstract][Full Text] [Related]
22. Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization.
Fan KY; Wild AT; Halappa VG; Kumar R; Ellsworth S; Ziegler M; Garg T; Rosati LM; Su Z; Hacker-Prietz A; Pawlik TM; Cosgrove DP; Hong KK; Kamel IR; Geschwind JF; Herman JM
Contemp Clin Trials; 2016 Sep; 50():143-9. PubMed ID: 27520932
[TBL] [Abstract][Full Text] [Related]
23. Yttrium-90 resin microsphere radioembolization using an antireflux catheter: an alternative to traditional coil embolization for nontarget protection.
Morshedi MM; Bauman M; Rose SC; Kikolski SG
Cardiovasc Intervent Radiol; 2015 Apr; 38(2):381-8. PubMed ID: 24989143
[TBL] [Abstract][Full Text] [Related]
24. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival.
Hoffmann RT; Paprottka PM; Schön A; Bamberg F; Haug A; Dürr EM; Rauch B; Trumm CT; Jakobs TF; Helmberger TK; Reiser MF; Kolligs FT
Cardiovasc Intervent Radiol; 2012 Feb; 35(1):105-16. PubMed ID: 21431970
[TBL] [Abstract][Full Text] [Related]
25. Molecular and Metabolic Imaging of Hepatic Neuroendocrine Tumors Following Radioembolization with 90Y-microspheres.
Filippi L; Cianni R; Schillaci O; Bagni O
Curr Med Imaging; 2020; 16(5):545-552. PubMed ID: 32484088
[TBL] [Abstract][Full Text] [Related]
26. Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study.
Xing M; Prajapati HJ; Dhanasekaran R; Lawson DH; Kokabi N; Eaton BR; Kim HS
Am J Clin Oncol; 2017 Feb; 40(1):27-34. PubMed ID: 25089529
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
[TBL] [Abstract][Full Text] [Related]
28. Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for hepatic neuroendocrine metastases: initial experience at a single center.
Arslan N; Emi M; Alagöz E; Ustünsöz B; Oysul K; Arpaci F; Uğurel S; Beyzadeoğlu M; Ozgüven MA
Vojnosanit Pregl; 2011 Apr; 68(4):341-8. PubMed ID: 21627019
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of Radioembolization in Patients with Chemorefractory Colorectal Cancer Liver Metastasis: a Single-Center Experience.
Türk G; Eldem G; Kılıçkap S; Bozkurt FM; Salancı BV; Çil BE; Peynircioğlu B; Yalçın Ş; Balkancı F
J Gastrointest Cancer; 2019 Jun; 50(2):236-243. PubMed ID: 29354877
[TBL] [Abstract][Full Text] [Related]
30. The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis.
Devcic Z; Rosenberg J; Braat AJ; Techasith T; Banerjee A; Sze DY; Lam MG
J Nucl Med; 2014 Sep; 55(9):1404-10. PubMed ID: 25012459
[TBL] [Abstract][Full Text] [Related]
31. Peptide Receptor Radionuclide Therapy in Patients With Advanced Progressive Medullary Thyroid Cancer: Efficacy, Safety, and Survival Predictors.
Liu Q; Kulkarni HR; Zhao T; Schuchardt C; Chen X; Zhu Z; Zhang J; Baum RP
Clin Nucl Med; 2023 Mar; 48(3):221-227. PubMed ID: 36723881
[TBL] [Abstract][Full Text] [Related]
32. Long-Term Hepatotoxicity of Yttrium-90 Radioembolization as Treatment of Metastatic Neuroendocrine Tumor to the Liver.
Su YK; Mackey RV; Riaz A; Gates VL; Benson AB; Miller FH; Yaghmai V; Gabr A; Salem R; Lewandowski RJ
J Vasc Interv Radiol; 2017 Nov; 28(11):1520-1526. PubMed ID: 28673658
[TBL] [Abstract][Full Text] [Related]
33. Radioembolization with Yttrium-90 Microspheres for the Treatment of Liver Metastases of Pancreatic Adenocarcinoma: A Multicenter Analysis.
Kim AY; Frantz S; Brower J; Akhter N
J Vasc Interv Radiol; 2019 Mar; 30(3):298-304.e2. PubMed ID: 30819469
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry.
Wong TY; Zhang KS; Gandhi RT; Collins ZS; O'Hara R; Wang EA; Vaheesan K; Matsuoka L; Sze DY; Kennedy AS; Brown DB
BMC Cancer; 2022 Mar; 22(1):224. PubMed ID: 35232410
[TBL] [Abstract][Full Text] [Related]
35. Dose-response relationship after yttrium-90-radioembolization with glass microspheres in patients with neuroendocrine tumor liver metastases.
Ebbers SC; van Roekel C; Braat MNGJA; Barentsz MW; Lam MGEH; Braat AJAT
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1700-1710. PubMed ID: 34873638
[TBL] [Abstract][Full Text] [Related]
36. Lung Shunt Fraction prior to Yttrium-90 Radioembolization Predicts Survival in Patients with Neuroendocrine Liver Metastases: Single-Center Prospective Analysis.
Ludwig JM; Ambinder EM; Ghodadra A; Xing M; Prajapati HJ; Kim HS
Cardiovasc Intervent Radiol; 2016 Jul; 39(7):1007-14. PubMed ID: 26964779
[TBL] [Abstract][Full Text] [Related]
37. Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.
Thang SP; Lung MS; Kong G; Hofman MS; Callahan J; Michael M; Hicks RJ
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):262-277. PubMed ID: 28894897
[TBL] [Abstract][Full Text] [Related]
38. Comparison of Choi criteria and Response Evaluation Criteria in Solid Tumors (RECIST) for intrahepatic cholangiocarcinoma treated with glass-microspheres Yttrium-90 selective internal radiation therapy (SIRT).
Beuzit L; Edeline J; Brun V; Ronot M; Guillygomarc'h A; Boudjema K; Gandon Y; Garin E; Rolland Y
Eur J Radiol; 2016 Aug; 85(8):1445-52. PubMed ID: 27423686
[TBL] [Abstract][Full Text] [Related]
39. Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases.
Barbier CE; Garske-Román U; Sandström M; Nyman R; Granberg D
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1425-31. PubMed ID: 26631239
[TBL] [Abstract][Full Text] [Related]
40. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.
Kennedy AS; Dezarn WA; McNeillie P; Coldwell D; Nutting C; Carter D; Murthy R; Rose S; Warner RR; Liu D; Palmedo H; Overton C; Jones B; Salem R
Am J Clin Oncol; 2008 Jun; 31(3):271-9. PubMed ID: 18525307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
